临床试验/JPRN-UMIN000052047

JPRN-UMIN000052047尚未招募Unknown

Ramucirumab plus Erlotinib as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR exon 21 L858R mutation: A multicenter retrospective observational cohort study in Japan (REAL-SPEED) - Ramucirumab plus Erlotinib as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR exon 21 L858R mutation: A multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Teikyo University0 个研究点目标入组 200 人开始时间: 2023年9月1日最近更新: 2023年10月17日

适应症

试验速览

阶段: Unknown
状态: 尚未招募
发起方: Teikyo University
入组人数: 200

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Observational

入排标准

年龄范围: ot applicable 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•Active double cancers* *Double cancers are synchronous double cancers and metachronous double cancers with a disease-free interval of <3 years, and lesions in carcinoma in situ or mucosal equivalent that are considered cured by local treatment should not be included in active double cancers.

研究者

发起方

Teikyo University

相似试验

进行中（未招募）

First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamiento de primera línea con rituximab combinado con fluradabina, ciclofosfamida y Mitoxantrone (R-FCM) y mantenimiento con rituximab de pacientes con leucemia linfática crónica (LLC) - R-FCM in CPatients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treated

EUCTR2005-001569-33-ESDept. Hematology, Hospital Clinic60

Ramucirumab and Erlotinib for NSCLC Patients with Brain Metastasesnon-small Cell Lung Cancer

JPRN-jRCTs051220059Takayama Koichi32

Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaStomach Neoplasms

JPRN-jRCT2080222764Eli Lilly Japan K.K.

进行中（未招募）

First line treatment with Rituximab asociated to CVP plus Interferon in Follicular Lymphoma. Phase II study.Asociación de Rituximab al esquema CVP + Interferón en el tratamiento de primera línea del linfoma folicular - R-CVP-IF

EUCTR2005-004761-42-ESFundacion Leucemia y Linfoma

进行中（未招募）

Rituximab plus Bendamustine as front line treatment in frail elderly (=70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL)

EUCTR2011-001421-24-ITFONDAZIONE ITALIANA LINFOMI ONLUS